SCIENTIFIC-PRACTICAL JOURNAL

| укр | рус |

 

 
Home Editorial ethics For authors Current issue Archive Contacts

No3(4) 2021

Back to the issue


DOI 10.37219/2528-8253-2021-3-45
Naumova O.O., Gogunska I.V., Smagina T.V., Nesterchuk V.I., Kholodenko T.Yu.
The role of beta-glucans in combined therapy of patients with seasonal allergic rhinitis
Naumova Olga A.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National Academy of Medical Sciences of Ukraine”; Kyiv, Ukraine
Center allergic diseases of the upper respiratory tract
Allergist
Candidate of Medical Sciences
Email: dr.onaumova@gmail.com

Gogunska Inna V.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National Academy of Medical Sciences of Ukraine”; Kyiv, Ukraine
Center allergic diseases of the upper respiratory tract
Doctor of Medical Sciences
e-mail: innagogunskaya@gmail.com
ORCID ID: 0000-0001-6952-5057

Smagina Tetyana V.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National
Department of Rhinology and Allergology with radiology group
Candidate of Medical Sciences
Email: amtc@kndio.kiev.ua

Nesterchuk Vladislav I.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National
Department of Rhinology and Allergology with radiology group
Candidate of Medical Sciences
Email: amtc@kndio.kiev.ua

Kholodenko Tetiana Yu.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National Academy of Medical Sciences of Ukraine”; Kyiv, Ukraine
Scientific Secretary
E-mail: amtc@kndio.kiev.ua
ORCID ID: https://orcid.org/0000-0002-6578-5799
Scopus Author ID: 6506250388

Abstract

Topicality: Beta-glucans are a group of biologically active polysaccharides of natural origin with a proven pleiotropic immunomodulatory effect. In vitro experiments as well as animal and human clinical studies proved the importance of beta-glucans in the treatment and prevention of allergic diseases. This opens up new prospects for the use of this widespread and popular group of natural substances.
Aim: to investigate whether the addition of "Bewell®" can alleviate the symptoms of seasonal AR in children
sensitized to ragweed during flowering and improve their quality of life.
Materials and methods: The study involved 30 patients (12 girls, 18 boys) aged from 6 to 12 years with a verified diagnosis of seasonal allergic rhinitis. Clinical manifestations of rhinoconjunctivitis were evaluated according to T5SS scale, quality of life (QOL) – according to Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ).
Results: The study found that administration of "Bewell®" in the complex therapy of seasonal allergic rhinitis significantly reduced rhinoconjunctival manifestations (p<0.001). The surveyed patients reduced consumption of antihistamines. After a treatment course, a decrease in the PRQLQ score was detected for such parameters as: irritability, need to wake up at night due to nasal congestion, need to take medications to relieve AR symptoms such as antihistamines or inhaled corticosteroids, which indicated an increase in the quality of life of patients after the therapy.
The use of a complex of parameters to evaluate the therapy effectiveness showed that the use of beta-1,3/1,6-glucan ("Bewell®") is promising for reducing AR symptoms in children, leading to their rapid regression, improving the quality of life and effective relief of AR symptoms. Administration of "Bewell®" reduces the need for concomitant therapy and helps to reduce the drug load.

Keywords

Beta-glucan, allergic rhinitis, children.


Reference

  1. Gupta R, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, Holl JL. The prevalence, severity and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):е9-17. DOI: 10.1542/ped.2011-0204.
  2. Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS. WAO White Book on Allergy: Update 2013, Executive Summary. World Allergy Organization (WAO). 2013.20p.
  3. Zaykov SV. [Modern strategies for diagnostics and treatment of allergic rhinitis]. Asthma and allergy. 2019;(4):64-5. [Article in Ukrainian].
  4. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1391-6.doi: 10.1164/ajrccm.162.4.9912033.
  5. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108(1 Suppl):45-53.
    doi: 10.1067/mai. 2001.115566.
  6. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. Jan-Feb 2007;28(1):3-9.doi: 10.2500/aap.2007.28.2934.
  7. Bergeron C, Hamid Q. Relationship between asthma and rhinitis: epidemiologic, pathophysiologic, and therapeutic aspects. Allergy Asthma Clin Immunol. 2005 Jun 15;1(2):81-7. doi: 10.1186/1710-1492-1-2-81.
  8. Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011;1(3):157-67. doi: 10.5415/apallergy.2011.1.3.157.
  9. Young MC. Rhinitis, sinusitis, and polyposis. Allergy Asthma Proc. 1998;19(4):211-8. doi: 0.2500/108854198778557890.
  10. BousquetJ, Van CauwenbergeP, KhaltaevN, Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147-334. doi: 10.1067/mai.2001.118891.
  11. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol. 2003;90(2):182-90; quiz 190-1, 232.
    doi: 10.1016/S1081-1206(10)62138-2.
  12. Austin JB, Kaur B, Anderson HR, Burr M, Harkins LS, Strachan DP. Hay fever, eczema, and wheeze: a nationwide UK study (ISAAC, international study of asthma and allergies in childhood). Arch Dis Child. 1999;81(3):225-30.
    doi: 10.1136/adc.81.3.225.
  13. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005;4(6):439-46. doi: 10.2165/00151829-200504060-00007.
  14. Allergies in America: a landmark survey of nasal allergy sufferers: executive summary. Florham Park, NJ: Altana Pharma US, Inc; 2006. Available from: http://www.myallergiesinamerica.com. Accessed June 1, 2009.
  15. Santos CB, Pratt EL, Hanks C, McCann J, Craig TJ. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol. 2006;97(5):579-86; quiz 586-9, 671. doi: 10.1016/S1081-1206(10)61084-8.
  16. Sundberg R, Torйn K, Hцglund D, Aberg N, Brisman J. Nasal symptoms are associated with school performance in adolescents. J Adolesc Health. 2007;40(6):581-3. doi: 10.1016/j.jadohealth.2007.01.003.
  17. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005;4(6):439-46.doi: 10.2165/00151829-200504060-00007.
  18. Delatte SJ, EvansJ, HebraA, AdamsonW, OthersenHB, TaggeEP. Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children.J Pediatr Surg. 2001;36(1):113-8. doi: 10.1053/jpsu.2001.20024.
  19. Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G, Forse RA. Effect of beta-glucan from oats and yeast on serum lipids. Crit Rev Food Sci Nutr. 1999;39(2):189-202. doi: 10.1080/10408399908500493.
  20. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered beta-glucans enhance antitumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002;51(10):557-64. doi: 10.1007/s00262-002-0321-3.
  21. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor
    models. J Immunol. 2004;173(2):797-806. doi: 10.4049/jimmunol.173.2.797.
  22. Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, Kim DW, Lee KH. Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae. Int Immunopharmacol. 2008;8(1):36-42. doi: 10.1016/j.intimp.2007.10.005.
  23. Driscoll M, Hansen R, Ding C, Cramer DE, Yan J. Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol Ther. 2009;8(3):218-25. doi: 10.4161/cbt.8.3.7337.
  24. Chen J, Seviour R. Medicinal importance of fungal beta-(1-->3), (1-->6)-glucans. Mycol Res. 2007;111(Pt 6):635-52. doi: 10.1016/j.mycres. 2007.02.011.
  25. Lukyanchuk VD, Mishchenko EM, Babenko MN. [Beta-glucans as a basis for creating immunomodulatory agents]. Ukraïnskyĭ medychnyĭ chasopys . 2011;85(5). [Article in Russian].
  26. Bohn JA, BeMille JN. (1→3)-β-d-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohyd Polym. 1995;28(1):3-14. Available from: https://www.sciencedirect.com/science/article/abs/
    pii/0144861795000763.
  27. Khimich TU. [The use of beta glucan as an immunomodulatory therapy in frequently and long-term ill patients]. Suchasna pediatria. 2014;61(5). [Article in Russian].
  28. Tsukada C, Yokoyama H, Miyaji C, Ishimoto Y, Kawamura H, Abo T. Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of β-glucan. Cell Immunol. 2003; 221(1): 1-5.
    doi: 10.1016/s0008-8749(03)00061-3.
  29. Sandula J, Machovб E, Hrнbalovб V. Mitogenic activity of particulate yeast beta-(1–>3)- D-glucan and its water-soluble derivatives. Int J Biol Macromol. 1995;17(6):323-6. doi: 10.1016/0141-8130(96)81839-3.
  30. Sarinho E, Medeiros D, Schor D, Rego SA, Sales V, Motta ME, et al. Production of interleukin-10 in asthmatic children after β-1-3-glucan. Allergol Immunopathol (Madr). 2009;37(4):188-92. doi: 10.1016/j.aller.2009.02.005.
  31. Moyad MA, Robinson LE, Kittelsrud JM, Reeves SG, Weaver SE, Guzman AI, Bubak ME. Immunogenic Yeast-Based Fermentation Product Reduces Allergic Rhinitis-Induced Nasal Congestion: a Randomized, Double-Blind, Placebo-Controlled
    Trial. Adv Ther. 2009;26(8):795-804. doi: 10.1007/s12325-009-0057-y.
  32. Jesenak M, Banovcin P, Rennerova Z, MajtanJ. β-Glucans in the treatment and prevention of allergic diseases. Allergol Immunopathol (Madr). 2014; 42(2):149-56.doi:10.1016/j.aller.2012.08.008.
  33. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol. 1998;101(2 Pt 1):163-70. doi: 10.1016/s0091-6749(98)70380-x.
  34. Talbott SM, Talbott JA, Talbott TL, Dingler E. b-Glucan supplementation, allergy symptoms, and quality of life in selfdescribed ragweed allergy sufferers. Food Sci Nutr. 2013;1(1):90-101. doi: 10.1002/fsn3.11.
  35. Yamada J, Hamuro J, Hatanaka H, Hamabata K, Kinoshita S. Alleviation of seasonal allergic symptoms with superfine β-1,3-glucan: a randomized study. J Allergy Clin Immunol. 2007;119(5):1119-26. doi: 10.1016/j.jaci.2007.02.005.
 

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»